multilayer tablet exclusion criteria from PK analysis due to emesis [Regulatives / Guidelines]

posted by Mahesh M – India, 2016-01-08 11:56 (3362 d 17:19 ago) – Posting: # 15803
Views: 5,973

Dear All,

My concern regarding multilayer tablet one API is IR and another is XR (combination of IR and XR) what is the exclusion criteria of subjects form PK analysis due to the emesis for FDA submission? Can we use different criteria for IR and XR as per FDA guidance or this combination product consider as modified release dosage form?

Regards
M

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,677 registered users;
14 visitors (0 registered, 14 guests [including 4 identified bots]).
Forum time: 05:16 CET (Europe/Vienna)

There are no routine statistical questions,
only questionable statistical routines.    David R. Cox

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5